Home / Market News / $RADX
benzinga Corporate Catalyst Impact 65/100 ● positive

Radiopharm Theranostics Announces Completion Of EOP2 Meeting With FDA Regarding RAD101, Investigational Radiopharmaceutical Imaging Agent For Detection Of Brain Metastases

Oct 5, 2026, 12:09 PM UTC · Primary ticker $RADX

Radiopharm Theranostics announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the FDA for its investigational imaging agent RAD101. This interaction provides a clear framework for the pivotal clinical development plan, indicating progress towards potential market approval for detecting brain metastases.

Radiopharm Theranostics (RADX) has successfully completed an End-of-Phase 2 meeting with the FDA for RAD101, an imaging agent for brain metastases. This is a significant step as it provides a clear framework for the pivotal Phase 3 clinical development, reducing regulatory uncertainty and outlining the path to potential market approval. The company is now executing Phase 3 readiness activities, indicating an accelerated timeline. This news is positive for RADX in the short term as it de-risks a key pipeline asset and could lead to increased investor confidence. Long-term implications depend on the success of the Phase 3 trials and eventual commercialization, but this marks a crucial regulatory milestone. The key opportunity for traders is the potential for upward movement as the company progresses towards Phase 3 and receives the official FDA minutes.

$RADX positive Regulatory progress for key pipeline asset
$RAD positive Regulatory progress for key pipeline asset (ASX listing)
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.